Line 1,765: |
Line 1,765: |
| |- | | |- |
| |[[HAEM5:Fluid overload-associated large B-cell lymphoma|Fluid overload-associated large B-cell lymphoma]]||Disease|| || || || || ||GC|| || | | |[[HAEM5:Fluid overload-associated large B-cell lymphoma|Fluid overload-associated large B-cell lymphoma]]||Disease|| || || || || ||GC|| || |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
| |- | | |- |
| |[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease|| || || || || ||GC|| || | | |[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease|| || || || || ||GC|| || |
− | | | + | |Plasmablastic Lymphoma |
| |Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) | | |Mark Evans, MD (University of California, Irvine) Fabiola Quintero-Rivera, MD (University of California, Irvine) |
− | | | + | |Complete |
− | | | + | |28/03/2022 |
| | | | | |
| |- | | |- |
| |[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease|| || || || || ||GC|| || | | |[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease|| || || || || ||GC|| || |
− | | | + | |Diffuse Large B-cell Lymphoma, Not Otherwise Specified + Primary Diffuse Large B-cell Lymphoma of the CNS |
− | |Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center | + | |Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital |
− | | | + | |Pending + Complete |
− | | | + | |Not ready + 03/28/22 |
− | | | + | |For "Diffuse Large B-cell Lymphoma, Not Otherwise Specified" page from Ash, Greg requested to update 14022022 |
| |- | | |- |
| |[[HAEM5:Primary cutaneous diffuse large B-cell lymphoma, leg type|Primary cutaneous diffuse large B-cell lymphoma, leg type]]||Disease|| || || || || ||GC|| || | | |[[HAEM5:Primary cutaneous diffuse large B-cell lymphoma, leg type|Primary cutaneous diffuse large B-cell lymphoma, leg type]]||Disease|| || || || || ||GC|| || |